Trump announces 100% tariff on import of patented pharma products, Pg1

Key Highlights:

• US President Donald Trump announced a 100% tariff on imported branded or patented pharmaceutical products, effective October 1, 2025.
• A 50% tariff will be imposed on kitchen cabinets, bathroom vanities, and related products, along with a 25% tariff on heavy trucks.
• The tariff is linked to companies establishing pharmaceutical manufacturing plants in the US, defined as "breaking ground" or "under construction".
• India's focus on generic drugs may initially shield it from the full impact, but uncertainty surrounds "branded generics".

Detailed Insights:

• The tariffs are initiated under Section 232 of the Trade Expansion Act of 1962, citing "national security" as justification.
• India's pharmaceutical exports to the US are significant, accounting for nearly 40% of its total pharma exports.
• Sun Pharma is identified as the only Indian company with substantial sales from patented products in the US, reporting $121.7 million in FY25.
• The move could impact government incentives under the Production-Linked Incentive (PLI) schemes, which support the manufacturing of patented drugs.
• European countries like Ireland, Switzerland, and Germany, which supply high-value branded drugs, are expected to face the most severe impact.
• India's exports to the US include pharmaceutical formulations for treating conditions like hypertension, diabetes, and infections, valued at $9.8 billion in 2024-25.

Key Concepts Involved:

• Tariff: A tax imposed on imported goods and services.
• Generics: Medications sold under the chemical name, not a brand name.
• Branded Generics: Generic drugs sold under brand names.
• Production-Linked Incentive (PLI) Scheme: A government scheme that gives incentives for enhancing domestic manufacturing.